Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204185128> ?p ?o ?g. }
- W3204185128 endingPage "250" @default.
- W3204185128 startingPage "236" @default.
- W3204185128 abstract "Epigenetic dysregulation leads to aberrant DNA hypermethylation and is common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). A large number of clinical trials in AML, MDS, and other hematologic malignancies have assessed hypomethylating agents (HMAs), used alone or in combination with other drugs, in the frontline, maintenance, relapsed/refractory, and peritransplant settings. Effective maintenance therapy has long been a goal for patients with AML in remission. Previous large, randomized clinical trials of maintenance with HMAs or other agents had not shown meaningful improvement in overall survival. Oral azacitidine (Oral-AZA [CC-486]) is approved in the United States, Canada, and European Union for treatment of adult patients with AML in first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy who are ineligible for hematopoietic cell transplant. Regulatory approvals of Oral-AZA were based on outcomes from the randomized, phase III QUAZAR AML-001 trial, which showed a median overall survival advantage of 9.9 months with Oral-AZA versus placebo. Oral-AZA allows convenient extended AZA dosing for 14 days per 28-day treatment cycle, which is not feasible with injectable AZA. Focusing on AML and MDS, this report reviews the rationale for the use of orally bioavailable AZA and its potential use in all-oral combination therapy regimens; the unique pharmacokinetic and pharmacodynamic profile of Oral-AZA compared with injectable AZA; the clinical safety and efficacy of Oral-AZA maintenance therapy in patients with AML in first remission and for treatment of patients with active MDS; and ongoing Oral-AZA clinical trials." @default.
- W3204185128 created "2021-10-11" @default.
- W3204185128 creator A5005591514 @default.
- W3204185128 creator A5015991333 @default.
- W3204185128 creator A5046911143 @default.
- W3204185128 creator A5061026876 @default.
- W3204185128 creator A5064895172 @default.
- W3204185128 creator A5089395073 @default.
- W3204185128 creator A5091318797 @default.
- W3204185128 date "2022-04-01" @default.
- W3204185128 modified "2023-10-15" @default.
- W3204185128 title "Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies" @default.
- W3204185128 cites W1415829101 @default.
- W3204185128 cites W1600365609 @default.
- W3204185128 cites W1615743071 @default.
- W3204185128 cites W1796660362 @default.
- W3204185128 cites W187238933 @default.
- W3204185128 cites W1883939012 @default.
- W3204185128 cites W1953890763 @default.
- W3204185128 cites W1963335440 @default.
- W3204185128 cites W1974079495 @default.
- W3204185128 cites W1975522050 @default.
- W3204185128 cites W1991858306 @default.
- W3204185128 cites W1999843227 @default.
- W3204185128 cites W2000252768 @default.
- W3204185128 cites W2000896040 @default.
- W3204185128 cites W2013657344 @default.
- W3204185128 cites W2017394727 @default.
- W3204185128 cites W2031006855 @default.
- W3204185128 cites W2036263818 @default.
- W3204185128 cites W2040596732 @default.
- W3204185128 cites W2048386285 @default.
- W3204185128 cites W2059465100 @default.
- W3204185128 cites W2060228790 @default.
- W3204185128 cites W2060311019 @default.
- W3204185128 cites W2060956017 @default.
- W3204185128 cites W2070012795 @default.
- W3204185128 cites W2077004848 @default.
- W3204185128 cites W2089524549 @default.
- W3204185128 cites W2102544902 @default.
- W3204185128 cites W2104076485 @default.
- W3204185128 cites W2106833395 @default.
- W3204185128 cites W2113950481 @default.
- W3204185128 cites W2118771330 @default.
- W3204185128 cites W2125062167 @default.
- W3204185128 cites W2125347906 @default.
- W3204185128 cites W2127289529 @default.
- W3204185128 cites W2129510594 @default.
- W3204185128 cites W2133124834 @default.
- W3204185128 cites W2134350774 @default.
- W3204185128 cites W2136848081 @default.
- W3204185128 cites W2148428508 @default.
- W3204185128 cites W2148965443 @default.
- W3204185128 cites W2157372635 @default.
- W3204185128 cites W2198196477 @default.
- W3204185128 cites W2260812679 @default.
- W3204185128 cites W2265091238 @default.
- W3204185128 cites W2313888337 @default.
- W3204185128 cites W2326726820 @default.
- W3204185128 cites W2346463552 @default.
- W3204185128 cites W2419140434 @default.
- W3204185128 cites W2426586472 @default.
- W3204185128 cites W2463012969 @default.
- W3204185128 cites W2509578420 @default.
- W3204185128 cites W2519424566 @default.
- W3204185128 cites W2536745143 @default.
- W3204185128 cites W2559537906 @default.
- W3204185128 cites W2594476871 @default.
- W3204185128 cites W2600535204 @default.
- W3204185128 cites W2739087647 @default.
- W3204185128 cites W2790304803 @default.
- W3204185128 cites W2800792260 @default.
- W3204185128 cites W2803889088 @default.
- W3204185128 cites W2808807711 @default.
- W3204185128 cites W2884246240 @default.
- W3204185128 cites W2885331395 @default.
- W3204185128 cites W2898284215 @default.
- W3204185128 cites W2899242749 @default.
- W3204185128 cites W2902760604 @default.
- W3204185128 cites W2904401218 @default.
- W3204185128 cites W2906457520 @default.
- W3204185128 cites W2909763242 @default.
- W3204185128 cites W2910591767 @default.
- W3204185128 cites W2912558146 @default.
- W3204185128 cites W2938879708 @default.
- W3204185128 cites W2941453345 @default.
- W3204185128 cites W2951914133 @default.
- W3204185128 cites W2969998705 @default.
- W3204185128 cites W2970425807 @default.
- W3204185128 cites W2976760128 @default.
- W3204185128 cites W2984246397 @default.
- W3204185128 cites W2989764345 @default.
- W3204185128 cites W2998901800 @default.
- W3204185128 cites W3004570383 @default.
- W3204185128 cites W3013239621 @default.
- W3204185128 cites W3015984203 @default.
- W3204185128 cites W3031156800 @default.
- W3204185128 cites W3032335069 @default.